← Back to Search

YCWS App for Sickle Cell Disease

N/A
Recruiting
Led By Miriam O. Ezenwa
Research Sponsored by University of Florida
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Is 18 years of age or older
Reports moderate to severe level of pain (>3 on 0-10 scale) related to SCD within previous 24 hours
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline through month 6
Awards & highlights

Study Summary

This trial is testing whether the You Cope, We Support intervention can help reduce stress and improve pain control in patients with sickle cell disease, while reducing opioid use.

Who is the study for?
This trial is for English-speaking adults over 18 with Sickle Cell Disease (SCD) who experience moderate to severe pain and use opioids. It's not for those who are legally blind, physically unable to complete the study tasks, or have been in a related feasibility study before.Check my eligibility
What is being tested?
The trial tests a mobile health app that helps manage stress and pain through self-monitoring and provides relaxation/distraction exercises called 'You Cope, We Support' (YCWS). Participants will either use the full YCWS program or just self-monitor with alerts/reminders.See study design
What are the potential side effects?
Since this intervention involves non-invasive techniques like monitoring and educational content rather than medication, significant side effects are not expected. However, users may experience discomfort from regular engagement with technology.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
I have experienced pain level above 3 due to SCD in the last 24 hours.
Select...
I have been diagnosed with sickle cell disease.
Select...
I use opioid painkillers as needed or regularly.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline through month 6
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline through month 6 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Opioid use
Pain intensity scale
Stress intensity scale

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Experimental GroupExperimental Treatment1 Intervention
(Self-monitoring of pain, stress, and opioid use + alerts/reminders + use of YCWS [three video banks of RDE + Support]). Self-monitoring, using video banks, and getting support elements comprise the YCWS intervention. The YCWS App is comprised of three tabs displayed across the top of the screen, namely, self-monitoring, video banks, and support. During the short-term trial (Weeks 1-8), patients will monitor their stress and pain daily and have access to three video banks from which to choose their daily intervention. We will send automated system-generated alerts/reminders every 24 hours to experimental group patients via phone call, text, or email to facilitate intervention use. During the long-term period (months 3-6), only system-generated alerts/reminders will be available.
Group II: Control GroupActive Control1 Intervention
(Self-monitoring of pain, stress, and opioid use + alerts/reminders). During efficacy trial (Weeks 1-8), patients will monitor their stress, pain, and opioid use daily. We will send system-generated alerts/reminders every 24 hours to patients via phone call, text, or email to facilitate data entry. During the long-term period (months 3-6), patients will continue to monitor their stress, pain, and opioid use daily and receive only system generated alerts/reminders via messaging service or staff cell phone.

Find a Location

Who is running the clinical trial?

National Institute of Nursing Research (NINR)NIH
585 Previous Clinical Trials
10,379,129 Total Patients Enrolled
University of FloridaLead Sponsor
1,350 Previous Clinical Trials
719,275 Total Patients Enrolled
Miriam O. EzenwaPrincipal InvestigatorUniversity of Florida

Media Library

Self-monitoring of pain, stress, and opioid use + alerts/reminders Clinical Trial Eligibility Overview. Trial Name: NCT04484272 — N/A
Sickle Cell Disease Research Study Groups: Control Group, Experimental Group
Sickle Cell Disease Clinical Trial 2023: Self-monitoring of pain, stress, and opioid use + alerts/reminders Highlights & Side Effects. Trial Name: NCT04484272 — N/A
Self-monitoring of pain, stress, and opioid use + alerts/reminders 2023 Treatment Timeline for Medical Study. Trial Name: NCT04484272 — N/A
~44 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top